Target intelligence / Profile preview

T-cell receptor beta variable 6 (TRBV6)

Target
TRBV6
Molecular classification
Receptor, Other
01

Overview

T-cell receptor beta variable 6 (TRBV6) is a germline-encoded segment of the variable region of the beta chain in the alpha-beta T-cell receptor (TCR) complex. It plays a fundamental role in adaptive immunity by participating in antigen recognition and the subsequent activation of T lymphocytes upon binding to peptide-major histocompatibility complex (pMHC) molecules. Unlike highly variable, clonally rearranged TCR regions, TRBV6 represents a conserved, non-clonal target that is consistently expressed across individuals and is highly prevalent among tumor-infiltrating lymphocytes (TILs) in various malignancies. In oncology, TRBV6 has emerged as a novel therapeutic target for precision immunotherapy. Drugs like invikafusp alfa (STAR0602), a first-in-class bispecific dual T-cell agonist, target TRBV6 to selectively activate and expand Vβ6-positive CD4+ and CD8+ T-cell populations. This selective activation, combined with co-stimulation (such as via fused IL-2), drives the expansion of clonally diverse effector memory T cells, enhancing anti-tumor immunity and promoting durable tumor clearance even in checkpoint inhibitor-resistant cancers.

Other names
T-cell receptor Vβ6T-cell receptor Vb6T-cell receptor Vbeta6TCR Vβ6TCR Vb6TCR Vbeta6TRBV6T cell receptor beta variable 6
02

Mechanism of action

Invikafusp alfa (STAR0602) is a bispecific dual T-cell agonist that selectively binds and activates Vβ6/Vβ10 T-cell receptors while delivering a co-stimulatory interleukin-2 (IL-2) signal in cis, promoting the expansion of clonally diverse effector memory T cells.

03

Biological functions

Immune responseSignal transductionT cell activationAntigen recognition
04

Disease associations

CancerInflammationInfectionOther
05

Safety considerations

Cytokine release syndrome (CRS)Off-target immune activationAutoimmunityInfusion-related reactions
06

Interacting drugs

Invikafusp alfa (STAR0602)
07

Biomarkers

Vβ6 T-cell prevalenceTumor mutational burden (TMB)Microsatellite instability-high (MSI-H)CD8+ T-cell expansionCD25 expression

Beyond the preview

Go deeper on T-cell receptor beta variable 6 (TRBV6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-cell receptor beta variable 6 (TRBV6).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call